Total Payments
$263,239
2024 Payments
$3,651
Companies
24
Transactions
288
Medicare Patients
2,768
Medicare Billing
$436,097
Payment Breakdown by Category
Other$155,398 (59.0%)
Consulting$68,783 (26.1%)
Travel$24,981 (9.5%)
Food & Beverage$7,419 (2.8%)
Research$5,730 (2.2%)
Education$927.49 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $146,998 | 71 | 55.8% |
| Consulting Fee | $68,783 | 27 | 26.1% |
| Travel and Lodging | $24,981 | 83 | 9.5% |
| Food and Beverage | $7,419 | 91 | 2.8% |
| Unspecified | $5,730 | 5 | 2.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,900 | 1 | 1.9% |
| Honoraria | $3,500 | 1 | 1.3% |
| Education | $927.49 | 9 | 0.4% |
Payments by Type
General
$257,508
283 transactions
Research
$5,730
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $66,956 | 59 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $60,986 | 60 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $33,990 | 33 | $0 (2019) |
| Genentech USA, Inc. | $27,434 | 23 | $0 (2019) |
| Lilly USA, LLC | $19,878 | 26 | $0 (2019) |
| Puma Biotechnology, Inc. | $16,314 | 21 | $0 (2020) |
| Clovis Oncology, Inc. | $10,560 | 11 | $0 (2020) |
| Amgen Inc. | $6,780 | 9 | $0 (2019) |
| Seagen Inc. | $5,370 | 4 | $0 (2020) |
| EISAI INC. | $4,978 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,651 | 4 | Novocure GmbH ($3,500) |
| 2023 | $1,307 | 12 | Novocure Inc. ($851.35) |
| 2022 | $20.11 | 1 | AstraZeneca Pharmaceuticals LP ($20.11) |
| 2021 | $64.04 | 4 | Novocure Inc. ($18.79) |
| 2020 | $21,167 | 18 | PFIZER INC. ($8,840) |
| 2019 | $111,882 | 107 | AstraZeneca Pharmaceuticals LP ($29,692) |
| 2018 | $106,050 | 122 | PFIZER INC. ($28,406) |
| 2017 | $19,097 | 20 | Novartis Pharmaceuticals Corporation ($6,161) |
All Payment Transactions
288 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $61.75 | General |
| Category: Oncology | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $26.54 | General |
| 05/01/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $63.09 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Novocure GmbH | — | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| 08/22/2023 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $146.01 | General |
| Category: Endo-Mechanical | ||||||
| 05/04/2023 | Novocure Inc. | — | Food and Beverage | Cash or cash equivalent | $162.10 | General |
| 04/22/2023 | Novocure Inc. | — | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| 04/22/2023 | Novocure Inc. | — | Food and Beverage | Cash or cash equivalent | $46.05 | General |
| 04/22/2023 | Novocure Inc. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 04/21/2023 | Novocure Inc. | — | Travel and Lodging | Cash or cash equivalent | $326.57 | General |
| 04/17/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $112.50 | General |
| 04/10/2023 | Novocure Inc. | — | Travel and Lodging | Cash or cash equivalent | $233.64 | General |
| 04/10/2023 | Novocure Inc. | — | Travel and Lodging | Cash or cash equivalent | $3.00 | General |
| 04/05/2023 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $155.41 | General |
| Category: VTE | ||||||
| 03/15/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Oncology | ||||||
| 11/30/2021 | PFIZER INC. | BOSULIF (Drug), RUXIENCE | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/19/2021 | ASD SPECIALTY HEALTHCARE, LLC | — | Food and Beverage | In-kind items and services | $18.02 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/17/2021 | Novocure Inc. | NovoTTF-100L (Device) | Food and Beverage | Cash or cash equivalent | $18.79 | General |
| Category: Oncology | ||||||
| 09/18/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2020 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| Category: Oncology | ||||||
| 08/18/2020 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $119.31 | General |
| 07/16/2020 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,945.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $785.42 | 1 |
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $475.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 214 | 436 | $192,294 | $37,350 |
| 2022 | 4 | 111 | 190 | $86,829 | $18,208 |
| 2021 | 1 | 57 | 123 | $19,680 | $19,681 |
| 2020 | 41 | 2,386 | 10,236 | $1.2M | $360,858 |
Total Patients
2,768
Total Services
10,985
Medicare Billing
$436,097
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 155 | $88,660 | $17,036 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 155 | $60,140 | $11,798 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 75 | $19,725 | $3,913 | 19.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 21 | $12,012 | $2,302 | 19.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $9,360 | $1,824 | 19.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 17 | $2,397 | $476.85 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 45 | 73 | $41,434 | $8,504 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 84 | $31,977 | $6,640 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $8,985 | $1,968 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 19 | $4,433 | $1,096 | 24.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 57 | 123 | $19,680 | $19,681 | 100.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 134 | 961 | $153,760 | $152,618 | 99.3% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2020 | 11 | 18 | $302,832 | $59,045 | 19.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 20 | 3,000 | $168,960 | $42,109 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 170 | 291 | $65,184 | $21,808 | 33.5% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 59 | 146 | $100,156 | $16,725 | 16.7% |
| 86300 | Immunologic analysis for detection of tumor antigen | Office | 2020 | 265 | 587 | $72,788 | $11,873 | 16.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 44 | 60 | $18,060 | $7,115 | 39.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 260 | 691 | $42,842 | $7,084 | 16.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 324 | 909 | $31,815 | $6,903 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 51 | 96 | $29,184 | $5,059 | 17.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 27 | 27 | $11,664 | $4,103 | 35.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 40 | $6,280 | $2,381 | 37.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 330 | 779 | $14,801 | $2,293 | 15.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 40 | 85 | $12,920 | $2,187 | 16.9% |
About Dr. Sami Diab, MD
Dr. Sami Diab, MD is a Medical Oncology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548244270.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sami Diab, MD has received a total of $263,239 in payments from pharmaceutical and medical device companies, with $3,651 received in 2024. These payments were reported across 288 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($146,998).
As a Medicare-enrolled provider, Diab has provided services to 2,768 Medicare beneficiaries, totaling 10,985 services with total Medicare billing of $436,097. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Aurora, CO
- Active Since 12/06/2005
- Last Updated 08/08/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1548244270
Products in Payments
- LYNPARZA (Drug) $56,957
- KISQALI (Drug) $32,197
- IBRANCE (Drug) $26,222
- TALZENNA (Drug) $23,200
- VERZENIO (Drug) $18,241
- Nerlynx (Drug) $13,964
- Kadcyla (Biological) $13,765
- Perjeta (Biological) $12,637
- Rubraca (Drug) $10,560
- XGEVA (Biological) $6,765
- TUKYSA (Drug) $5,370
- Halaven (Drug) $4,967
- NINLARO (Drug) $2,828
- NERLYNX (Drug) $2,350
- Herceptin (Biological) $1,032
- Enhertu (Drug) $1,028
- PIQRAY (Drug) $632.08
- FASLODEX (Drug) $300.00
- FLOWTRIEVER CATHETER, S (Device) $155.41
- Monarch Platform (Device) $146.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Aurora
David Camidge, Md, MD
Medical Oncology — Payments: $815,418
Medical Oncology $815,418
Paul Bunn, Md, MD
Medical Oncology — Payments: $568,786
Medical Oncology $568,786
Karl Lewis, Md, MD
Medical Oncology — Payments: $170,530
Medical Oncology $170,530
Robert Doebele, Md, MD
Medical Oncology — Payments: $130,703
Medical Oncology $130,703
Dr. Victor Villalobos, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $99,277
Medical Oncology $99,277
Sunnie Kim, M.d, M.D
Medical Oncology — Payments: $72,304
Medical Oncology $72,304